Literature DB >> 20217424

The integrity of colonic anastomoses following the intraperitoneal administration of oxaliplatin.

Konstantinos Blouhos1, Manousos-Georgios Pramateftakis, Theodor Tsachalis, Dimitrios Kanellos, Thomas Zaraboukas, Georgios Koliakos, Dimitrios Betsis.   

Abstract

INTRODUCTION: The purpose of this experimental study was to determine the effect of oxaliplatin on the integrity of colonic anastomoses which were under oxaliplatin administration.
MATERIALS AND METHODS: Thirty rats were randomized to two groups. After resection of a 1-cm segment of the transverse colon, an end-to-end sutured anastomosis was performed. Rats of the control group were injected with 3 ml of 0.9% sodium chloride solution and in the oxaliplatin group with 2.4 mg/kg of oxaliplatin intraperitoneally immediately after surgery and for seven postoperative days. All rats were sacrificed on the tenth postoperative day, and the anastomoses were examined macroscopically and graded histologically. Rats were measured for anastomotic bursting pressures and tissue hydroxyproline levels.
RESULTS: The body weight changes were significantly greater in the oxaliplatin group (p = 0.005). Anastomotic dehiscence occurred only in the oxaliplatin group. The adhesion formation was significantly increased in the group of oxaliplatin compared to the control group (p = 0.001). The colonic bursting pressure was significantly lower in the oxaliplatin group compared to the control group (p < 0.001). The mean inflammatory cell infiltration was significantly lower in the oxaliplatin group (1.00 vs. 2.33, p < 0.001). The mean neoagiogenesis was significantly lower in the oxaliplatin group (0.80 vs. 2.20, p < 0.001). The mean collagen deposition was significantly lower in the oxaliplatin group and the mean fibroblast activity was significantly lower in the oxaliplatin group (1.27 vs. 2.53, p < 0.001). Hydroxyproline concentration was significantly lower in the oxaliplatin group (p < 0.001).
CONCLUSION: Intra- and postoperative intraperitoneal administration of oxaliplatin definitely impairs healing of colonic anastomoses in rats.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20217424     DOI: 10.1007/s00384-010-0912-y

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  45 in total

1.  Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial.

Authors:  J C Vaillant; B Nordlinger; S Deuffic; J P Arnaud; E Pelissier; J P Favre; D Jaeck; G Fourtanier; J P Grandjean; P Marre; C Letoublon
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

2.  The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.

Authors:  M Scartozzi; A Sobrero; G Gasparini; R Berardi; V Catalano; F Graziano; S Barni; A Zaniboni; G D Beretta; R Labianca; S Cascinu
Journal:  Oncology       Date:  2005-07-07       Impact factor: 2.935

3.  Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model.

Authors:  J O W Pelz; J Doerfer; M Decker; A Dimmler; W Hohenberger; T Meyer
Journal:  Int J Colorectal Dis       Date:  2007-01-24       Impact factor: 2.571

4.  Influence of intraperitoneal 5-fluorouracil plus folinic acid on the healing of colonic anastomoses in rats.

Authors:  I Kanellos; A Kavouni; T Zaraboukas; C Odisseos; K Galovatsea; I Dadoukis
Journal:  Eur Surg Res       Date:  1996       Impact factor: 1.745

5.  5-fluorouracil selectively inhibits collagen synthesis.

Authors:  Neil W Bulstrode; Vivek Mudera; D Angus McGrouther; Adriaan O Grobbelaar; Alison D Cambrey
Journal:  Plast Reconstr Surg       Date:  2005-07       Impact factor: 4.730

6.  Healing of colonic anastomoses after immediate postoperative intraperitoneal administration of oxaliplatin.

Authors:  Dimitrios Kanellos; Manousos-Georgios Pramateftakis; Haralampos Demetriades; Emmanouil Zacharakis; Stamatios Angelopoulos; Ioannis Mantzoros; Ioannis Kanellos; Kalliopi Despoudi; Thomas Zaraboukas; Georgios Koliakos; Kalliopi Galovatsea; Haralampos Lazaridis
Journal:  Int J Colorectal Dis       Date:  2008-08-02       Impact factor: 2.571

7.  Healing of colon anastomoses covered with fibrin glue after immediate postoperative intraperitoneal administration of 5-fluorouracil.

Authors:  I Kanellos; I Mantzoros; H Demetriades; S Kalfadis; T Kelpis; L Sakkas; D Betsis
Journal:  Dis Colon Rectum       Date:  2004-02-26       Impact factor: 4.585

Review 8.  [Adjuvant systemic chemo- or immunotherapy of colon cancer].

Authors:  P M Schlag
Journal:  Chirurg       Date:  1994-06       Impact factor: 0.955

Review 9.  Oxaliplatin: a review of preclinical and clinical studies.

Authors:  E Raymond; S G Chaney; A Taamma; E Cvitkovic
Journal:  Ann Oncol       Date:  1998-10       Impact factor: 32.976

10.  Influence of 5-fluorouracil and folinic acid on colonic healing: an experimental study in the rat.

Authors:  W Graf; S Weiber; B Glimelius; H Jiborn; L Påhlman; B Zederfeldt
Journal:  Br J Surg       Date:  1992-08       Impact factor: 6.939

View more
  3 in total

1.  The effect of bevacizumab on colon anastomotic healing in rats.

Authors:  Efstathios T Pavlidis; Konstantinos D Ballas; Nikolaos G Symeonidis; Kyriakos Psarras; Georgios Koliakos; Kokona Kouzi-Koliakos; Konstantina Topouridou; Savas F Rafailidis; Theodoros E Pavlidis; Georgios N Marakis; Athanasios K Sakantamis
Journal:  Int J Colorectal Dis       Date:  2010-08-06       Impact factor: 2.571

2.  Effects of melatonin on colonic anastomosis healing following chemotherapy in rats.

Authors:  Cebrail Akyuz; Necdet Fatih Yasar; Orhan Uzun; Kıvanc Derya Peker; Oguzhan Sunamak; Mustafa Duman; Ahmet Ozer Sehirli; Sinan Yol
Journal:  Singapore Med J       Date:  2018-03-19       Impact factor: 1.858

Review 3.  Our 20-year experience with experimental colonic anastomotic healing.

Authors:  Dimitrios Raptis; Manousos-Georgios Pramateftakis; Ioannis Kanellos
Journal:  J Med Life       Date:  2018 Jan-Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.